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Pharmacy benefit management (PBM) programs provide attractive discounts for drug purchase, a relevant 
measure to address costs, mainly of drugs for the treatment of chronic diseases. This study investigated 
whether PBM may be used as a tool to provide information about the use of antihypertensive medications 
when they are purchased. The profile of medicines taken to treat high blood pressure by large IT company 
employees and their dependents was evaluated from January to December 2009. The mean rate of drug 
boxes purchased to control hypertension was 9.4 ± 10.0 in 2009. Men purchased more drugs than women. 
The number of drugs purchased for the treatment of hypertension was lower than expected in all age 
groups except for individuals aged 54-58 and >59 years. Among men, the purchase of drugs to treat 
hypertension was higher than expected in the 24-28, 34-38 and 54-58 age groups. Among women, results 
matched expectations, except for the age group 34-38 years, in which purchase was lower than expected. 
Individuals in the age group 0-18 years were found to consume antihypertensive drugs. Although the 
PBM system may be used to identify drugs purchased by users, it does not ensure patient adherence to 
recommended drug treatment to control hypertension.
Uniterms: Hypertension. Antihypertensive drugs. Drugs/continuous use. Antihypertensive medications/
use. Treatment adherence. Drug therapy/adherence to treatment. Medicines/benefit manegement. 
O objetivo do Programa de Benefícios em Medicamentos (PBM) é proporcionar descontos atraentes 
para aquisição de medicamentos, um fator relevante para o custo, principalmente no tratamento de 
doenças crônicas. O objetivo deste estudo é comprovar se o PBM pode ser utilizado como ferramenta 
para o fornecimento de informações sobre o consumo de medicamentos antihipertensivos através da 
aquisição dos mesmos. Foi realizada análise do perfil de medicamentos adquiridos para o tratamento 
de hipertensão arterial sistêmica por funcionários e seus dependentes de uma empresa de grande porte 
na área de tecnologia de informação (TI) no período compreendido entre janeiro a dezembro de 2009. 
A taxa de aquisição média de medicamentos para o controle da hipertensão foi de 9,4±10,0 embalagens 
durante o ano de 2009. Os homens consumiram mais caixas de medicamentos que as mulheres. O número 
de caixas de medicamentos adquiridas para o tratamento da hipertensão arterial foi abaixo do esperado 
em todas as faixas de idade, exceto para 54-58 e >59 anos. Entre os homens, a aquisição de caixas de 
medicamentos para o tratamento da hipertensão arterial foi maior que o esperado nas seguintes faixas 
de idade: 24-28, 34-38 e 54-58 anos. Entre as mulheres, a aquisição de caixas de medicamentos anti-
hipertensivos foi dentro do esperado, exceto para aquelas com idade compreendida entre 34-38 anos que 
foi abaixo do esperado. Observou-se a existência de consumo de fármacos antihipertensivos na faixa 
etária de 0-18 anos. Embora o sistema de PBM permita identificar a aquisição de medicamentos anti-
hipertensivos por seus usuários, não garante que os pacientes estejam aderidos à terapia medicamentosa 
recomendada para o controle da hipertensão.
Unitermos: Hipertensão. Fármacos anti-hipertensivos. Anti-hipertensivos/uso. Medicamentos de uso 
contínuo. Terapia medicamentosa/adesão ao tratamento. 
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INTRODUCTION
Access to medicines is an indicator of both quality 
and effectiveness of the public health system, as well as 
a determinant factor for patient adherence to prescription 
treatments, mainly in the treatment of chronic degenerative 
diseases, such as high blood pressure (Halal et al., 1994; 
Paniz et al., 2008).
Although public healthcare services and systems in 
Brazil have progressed positively, their main challenge is 
to provide the population access to essential medicines. 
According to Guerra Jr. et al (2004) and Vieira and Zuc-
chi (2007), more than 70 million Brazilians had no access 
to medicines in 2000. This is a matter of concern because 
medicines are an essential issue for effective health care. 
High blood pressure is defined as an asymptomatic 
disease (Sociedade Brasileira de Cardiologia, 2010) 
whose symptoms are observed only when complications 
(mainly cardiovascular) occur. It increases costs of both 
hospital admissions and specialized treatments (Socie-
dade Brasileira de Cardiologia, Sociedade Brasileira de 
Hipertensão, Sociedade Brasileira de Nefrologia, 2010). 
According to data published by the Brazilian Ministry 
of Health, more than 1,150,000 hospital admissions per 
year are recorded in the Unified Health System (Sistema 
Único de Saúde, SUS) at a total cost of US$ 305 million 
(R$475 million; Brasil, 2009). Non-transmissible chronic 
diseases are also one of the main causes of disability 
retirement and temporary disability (Moura, Carvalho, 
Silva, 2007).
Because systemic hypertension usually presents in 
its asymptomatic form, many hypertensive individuals 
are either not identified or have low treatment compli-
ance after diagnosis. One of the reasons for low treat-
ment compliance is associated with social conditions, 
especially purchase of expensive medicines (Mion Jr. et 
al., 2006; Lessa, 2006) and treatment complexity, when 
the patient has to take many doses per day (Sica, 2002). 
The annual cost for treatment of hypertension in the Uni-
fied Health System (Sistema Único de Saúde, SUS) was 
US$ 621,302,202.56 (R$ 969,231,436.00), and in the 
National Supplementary Health Agency (NSHA), US$ 
424,773,685.90 (R$ 662,646,950.00). The total cost of 
hypertension treatment accounted for 0.08% of the Brazil-
ian gross domestic product (Produto Interno Bruto, PIB) 
in 2005 (Sociedade Brasileira de Cardiologia, Sociedade 
Brasileira de Hipertensão, Sociedade Brasileira de Ne-
frologia, 2010).
The study of consumption of antihypertensive 
drugs may be greatly valuable for patient monitoring. 
The investigation of cost/utility, cost/effectiveness, or 
cost/benefit ratios in the use of medicines should include 
all costs associated with the treatment of patients, includ-
ing medical visits, hospital admission, laboratory tests, 
nursing care, and social and mental health services (São 
Paulo, 2010). However, because of the difficulties in 
conducting complete analyses of treatment costs, several 
studies are limited to comparisons between costs of dif-
ferent medicines, which should be those at the time the 
medicine is prescribed because treatment indications last 
for the patient’s lifetime (Pearce et al., 1998). Therefore, 
private interests in drug development and provision have 
increased to ensure investments in both health care and 
drug management to minimize costs of non-drug treat-
ments and reduce inadequate treatments and possible 
undesirable hospital admissions (Sousa, 2010).
Of the drug benefits offered by managed health care 
companies, the most sought by users is the pharmacy 
benefit management - PBM (Programa de Benefícios 
em Medicamentos, PBM), which facilitates access to 
medicines (Agência Nacional de Saúde Suplementar, 
ANS; Brasil, 2010a). However, few studies have in-
vestigated the potential of the PBM program in Brazil. 
According to Lima et al. (2008), the PBM program com-
prises independent managed health care companies that 
manage benefits while selling medicines based on cost 
minimization, value aggregation, and strengthening of 
trade relationships to obtain operational advantages that 
meet the interests of the main agents involved: employers 
(companies that contract the system and pharmaceutical 
retailing), drugstores, and the pharmaceutical industry. 
However, the PBM system also seems to be able to pro-
vide relevant information about the profile of antibiotic 
prescription and purchase.
The databases of PBM companies are made up of 
information obtained from medicine purchases using a 
PBM card at licensed drugstores, and data are stored in 
an authorizer on-line server. This study described the 
characteristics of antihypertensive drug consumption ac-
cording to drug class and number of packages purchased 
using data about the purchase of drugs to control high 
blood pressure.
MATERIAL AND METHODS
The database used in this study was obtained from 
a PBM agency in the city of São Caetano do Sul, Brazil, 
which also has employees also in other Brazilian states 
(Rio de Janeiro, Rio Grande do Sul, Ceará, and Distrito 
Federal). In this IT company, PBM is one of the benefits 
provided to all active and retired employees and their de-
pendents. This benefit provides a 75% discount rate for the 
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TABLE I - Purchase of medicine boxes according to sex (January-
December, 2009)
Sex Mean value SD
Confidence interval
LL UL
Male * 10.3 10.4 9.8 10.8
Female 8.3 9.4 7.7 8.8
Total 9.4 10.0 9.0 9.7 
* p≤0.05; SD: standard deviation; LL: lower limits; UL: 
upper limits; Level of significance: 0.001.
purchase of prescribed medicines. It also records medicine 
prescriptions and their purchase by all employees and their 
dependents.
The database is built as beneficiaries use their PBM 
cards at the licensed drugstores when paying for antihy-
pertensive medication. Information in the card ensures 
online authorization, confirms the recipient’s eligibility for 
benefits under the PBM program, and validates data. The 
following items are recorded at the time of purchase: the 
registration number of the prescriber, the expiration date of 
the prescription, name, age and sex of the beneficiary, the 
number of boxes, name of the medicines and drug class. 
Finally, a confirmation of purchased drugs withdrawal is 
delivered to the beneficiary for salary discounts. Medical 
reports from this database are obtained using Excel 2007 
and provided to the managers of companies that contracted 
this benefit.
The IT company had 31,000 records of active em-
ployees, retirees and dependents who were entitled to the 
medicine benefits. All antihypertensive drugs used by 
the PBM beneficiaries in the IT company from January 
to December 2009, regardless of beneficiary age, were 
included in the study. Medicines not used in the treatment 
of high blood pressure were not included. In 2009, 2,798 
(9.03%) employees (1,537 men) purchased antihyperten-
sive medicines using the PBM program. A medicine profile 
was outlined according to sex and age range.
To ensure data confidentiality, the IT company, 
prescribers and patients were not identified. This study 
was approved by the Research Ethics Committee of the 
Municipal University of São Caetano do Sul.
The Anatomical Therapeutic Chemical (ATC) clas-
sification system, established by the World Health Orga-
nization (World Health Organization, 2010), was used to 
analyze antihypertensive drugs. Data were analyzed using 
the Statistical Package for the Social Sciences (SPSS) 
17.0 for Windows. Quantitative variables are described as 
frequency and measures of central tendency and disper-
sion. The Mann-Whitney U test was used to compare sex 
differences and the level of significance was set at 0.05 
(Hair et al., 2005; Pestana and Gageiro, 2008).
RESULTS
Table I shows that each employee purchased a mean 
9.4 ± 10.0 medicine boxes during the time under study. 
Men purchased more drugs than women (p≤0.001). 
Table II shows the mean number of medicine boxes 
purchased by different age groups. A CI-based classifica-
tion was derived from results, as “low”, “expected”, and 
“high”, for mean values that are bellow, within, or above 
the CI. Therefore, based on the 95% confidence interval 
(95%CI), the number of medicine boxes purchased was 
lower than expected for all age groups, except for the 
groups 54-58 and >59 years, both with results above 
expected. 
As indicated by 95% IC values and shown in Fi-
gure 1, the number of medicine boxes purchased by men 
was expected in the age groups 0-18, 19-23, 29-33, 39-
43, 44-48, 49-53, and > 59 years. In the other age groups 
(24-28, 34-38, and 54-58), consumption was higher than 
expected. Among women, the purchase of medicine boxes 
was expected for all age groups except in the group 34-38 
years, in which it was lower than expected.
Table III shows that the purchase of β blockers 
(31.3%) was the highest, followed by pure (29.0%) and 
combined angiotensin II antagonists (25.7%), and pure 
ACE inhibitors (19.9%) and calcium antagonists (17.3%), 
but there were no statistical differences.
TABLE II - Purchases of medicine boxes in 2009 according to 







0-18 2.5 1.2 1.2 3.8
19-23 2.3 2.8 0.5 4.1
24-28 4.7 4.8 3.4 6.1
29-33 6.1 7.1 5.2 6.9
34-38 6.8 9.0 5.7 7.9
39-43 7.3 7.0 6.4 8.0
44-48 8.1 10.5 6.9 9.3
49-53 8.7 8.6 7.7 9.6
54-58 10.1 10.8 9.1 11.2
> 59  12.5 11.0 11.7 13.2
* p≤0.05; SD: standard deviation; LL: lower limits; UL: upper 
limits; Level of significance: 0.001
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FIGURE 1 - Purchases of medicine boxes according to sex and age group (January-December, 2009).





N (%) N (%) N (%)
β blockers 456 (16.3) 421 (15.0) 877 (31.3)
Potassium-sparing diuretics + loop diuretics 7 (0.25) 10 (0.3) 17 (0.6)
Potassium-sparing diuretics + thiazide diuretics (and/or analogs) 80 (2.9) 76 (2.7) 156 (5.6)
Potassium-sparing diuretics 48 (1.7) 84 (3.1) 132 (4.7)
Angiotensin II antagonists (combined) 429 (15.3) 290 (10.4) 719 (25.7)
Angiotensin II antagonists (pure) 498 (17.8) 314 (11.2) 812 (29.0)
Calcium channel blockers + β blockers 12 (0.4) 7 (0.25) 19 (0.7)
Calcium channel blockers 280 (10.0) 203 (7.3) 486 (17.3)
Centrally-acting agonists 13 (0.5) 36 (1.3) 49 (1.7)
Peripherally-acting adrenergic antagonists 10 (0.4) 7 (0.25) 17 (0.6)
Antihypertensive drugs + diuretics 98 (3.5) 91 (3.25) 189 (6.7)
Loop diuretics 65 (2.3) 88 (3.1) 153 (5.5)
ACE inhibitors + calcium channel blockers 46 (1.6) 23 (0.8) 69 (2.5)
ACE inhibitors + antihypertensive drugs 66 (2.3) 38 (1.3) 104 (3.7)
ACE inhibitors 332 (11.9) 224 (8.0) 556 (19.9)
Other diuretics 0 0 2 (0.07) 2 (0.07)
Thiazide diuretics and analogs 201 (7.2) 220 (7.9) 421 (15.0)
TOTAL 1537 (54.9) 1261 (45.1) 2798 (100)
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DISCUSSION
Data from the Ministry of Health show that high 
blood pressure affects 24.4% of the Brazilian population, 
and this rate is as high as 50% in the age range of 50-59 
years, reaching 75% among persons aged > 75 years (Ce-
sarino et al. 2008; Rosario et al. 2008). The prevalence of 
hypertension among men is higher (35.8%) than among 
women (30%) (Pereira et al. 2009).
Other studies showed that several measures, such as 
continuous medicine therapy, changes in life style (edu-
cation and self care), and regular medical visits, are used 
to control high blood pressure. However, Péres, Magna, 
Viana (2003) confirmed other studies that found that the 
challenge in blood pressure control lies in patient adher-
ence to treatment, because patients with hypertension 
usually do not adhere to treatment and, among those who 
adhere, few have their high blood pressure controlled.
In Brazil, the government is responsible for provid-
ing health care as a fundamental right of all human beings, 
and should formulate and execute economic and social 
policies to ensure universal and equal access to health 
care, as well as health promotion, protection, and recovery 
(Brasil, 1990). At the same time, about 44 million Brazil-
ians are beneficiaries of individual or collective managed 
health care programs in the country (Agência Nacional de 
Saúde Suplementar, Brasil, 2010b).
In this context in Brazil and as an essential part 
of the National Health Policy (NHP; Política Nacional 
de Saúde, PNS), the objective of the National Medicine 
Policy (NMP; Política Nacional de Medicamentos, PNM) 
is to provide access and rational use of essential medicines 
to the population and to ensure safety, efficacy, and qual-
ity (Brasil, 2000). The NMP guidelines are directed to 
the revision of the National List of Essential Medicines 
(NLEM; Relação Nacional de Medicamentos Essenci-
ais, RENAME), the regulation of medicines by health 
care authorities, technical and scientific development, 
development and qualification of human resources, and 
the reorganization of pharmaceutical assistance (Oliveira, 
Labra, Bermudez, 2006).
The Brazilian Ministry of Health created the Popular 
Pharmacy Program (PPP; Programa Farmácia Popular, 
PFP) to amplify population access to medicines. PPP has 
its own popular pharmacy network, currently with 108 
medicines for the treatment of patients with dyslipidemia, 
diabetes, and high blood pressure. Such medicines are 
dispensed at reference values, with a reduction of up to 
90% of the value charged in commercial pharmacies and 
drugstores, and can only be purchased with a medical pre-
scription (Brasil, 2010c). Recently, the campaign “health is 
priceless” has been launched to provide free medications 
indicated for the treatment of hypertension and diabetes 
in pharmacies licensed by the PPP (Programa Farmácia 
Popular, PFP, Brasil, 2011).
However, according to the National Council of 
State Secretaries of Health (NCSSH; Conselho Na-
cional de Secretários Estaduais de Saúde, CONASS, 
2010), medicines in Brazil and Uruguay have the highest 
prices in the American continent. In addition, there is no 
information on the degree of success of the treatments 
prescribed. Because there is not a system to follow the 
treatment of patients, a pharmacy assistance program 
to verify and follow up patient adherence to treatment 
should be implemented to ensure adequate changes in 
treatment protocols.
According to Lima et al. (2008), PBM was created in 
the US in the 1970s when labor unions required employers 
to include medicines in their benefit programs. Between 
the late 1980s and early 1990s, the demand for prescribed 
medicines from PBM had a 30% increase. The action of 
managed care companies, cost managers in the health area, 
and the spread of PBM companies led to a large increase 
in the consumption of medicines in the USA. In Brazil, 
the concept of PBM is relatively new and appeared in the 
market in the late 1990s.
According to Taniguchi (1995), the main functions 
of PBM are: 
1. Deal with the drugstore chains to ensure that acces-
sible geographical sites are available to recipients;
2. Process medicine requests trough a network of drug-
stores where request transmission is automatic and 
based on the eligibility rules established between the 
contracting companies;
3. Send customized reports to the operators to ensure 
cost management and medicine consumption;
4. Create health compliance and disease management 
programs that inform the contracting companies 
about patients that do not follow the treatment as 
recommended by the physicians. Besides giving 
information to the contracting companies, PBM 
physicians and pharmacists carry out programs to 
educate chronic users, develop their self-knowledge 
and encourage lifestyle changes, always according 
to guidelines from medical societies;
5. Obtain discounts from the pharmaceutical industry 
after negotiations so that their medicines are in-
cluded in the basic PBM lists, which are based on 
medical consensus and enable users to choose one of 
a group of drugs in the same therapeutic class. The 
lists are reviewed and updated by the pharmaceutical 
and clinical committee of the PBM, and;
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6. Evaluate treatment outcomes according to the da-
tabase that includes all health care data (medicine 
requests, treatment compliance, and medicine 
consumption), which enables the development of 
adequate tools to monitor the incidence of events.
In the company studied, 9.03% of the individu-
als who used the pharmacy benefit purchased a mean 
9.4±10.0 boxes of antihypertensive drugs. Men pur-
chased more drugs than women, which may be explained 
by a higher prevalence of high blood pressure among 
men. Men tend to seek health care less frequently (un-
healthy behavior) than women (Gomes et al. 2007; 
Figueiredo, 2005). Regarding age range, purchase of 
antihypertensive drugs by men was higher than expected 
among those aged 24-28, 34-38, and 54-58 years. Among 
men in the other age groups, purchase was within the 
expected range. In the female population, purchase was 
expected in all age groups, except among women aged 
34-38 years, in which case the number of purchases was 
lower than expected.
In this study, purchase of antihypertensive drugs by 
people aged 0-18 years was remarkable. In Brazil, about 
3.5 million children and teenagers (5% of the Brazilian 
population) have hypertension (Sociedade Brasileira 
de Cardiologia, Sociedade Brasileira de Hipertensão e 
Sociedade Brasileira de Nefrologia, 2010). Under physi-
ological conditions, systolic blood pressure increases from 
the age of one year until adolescence, whereas diastolic 
blood pressure increases only after the age of 5-6 years 
(NIH, 2004).
According to some studies, the prevalence of high 
blood pressure has a secondary cause among young chil-
dren, and may include pathologies such as thrombosis, 
renal artery stenosis, and coarctation of the aorta. At the 
same time, primary hypertension is prevalent among ado-
lescents (Araújo et al., 2007). Studies show that lifestyle-
related factors, such as nutrition, lipid profile, obesity, 
sedentary habits, and tobacco smoking are potential causes 
of atherosclerosis whose contribution begins in childhood 
(Araújo et al., 2007; Lancarotte, 2010; Nobre et al., 2006; 
Pellanda et al., 2002).
In this study, β-blockers were the antihypertensive 
drugs with the highest consumption (31.3%). According 
to Machuca and Parras (2003), β-adrenergic blockers are 
among the first-choice drugs for the treatment of patients 
with systemic hypertension because they decrease both 
heart rate and myocardial contractility in addition to de-
creasing blood-pressure levels. However, diuretics are the 
most frequently used antihypertensive drugs because they 
cause a significant decrease in morbidity and mortality 
(Sociedade Brasileira de Cardiologia, 2010). In addition, 
they are less expensive and more efficient in preventing 
one or more main forms of cardiovascular disease.
According to Ribeiro (2005), the use of antihyper-
tensive drugs for the treatment of patients with this disease 
is essential. However, single-drug treatments result in 
reductions of systolic and diastolic pressures of only 4-8% 
of the initial values. At the same time, patients treated with 
the combination or association of two antihypertensive 
drugs may show an 8-15% decrease in blood pressure 
levels. In addition, the prescription of medicines with few 
side effects is increasingly frequent due to concerns about 
both compliance with the prescribed treatment and patient 
quality of life.
Milagres et al. (2005) suggest that angiotensin I 
converting enzyme (ACE) inhibitors should receive atten-
tion because of their low incidence of side effects, such as 
cough and headaches. In turn, drug treatments and lifestyle 
changes are highly recommended because reductions in 
sodium intake, body weight control, and regular physical 
activity reduce morbidity and mortality due to cardio-
vascular diseases (Sociedade Brasileira de Cardiologia, 
Sociedade Brasileira de Hipertensão, Sociedade Brasileira 
de Nefrologia, 2010).
The fact that patients purchase their medicines us-
ing the PBM program does not ensure their adherence to 
treatment. Many reasons may explain nonadherence, such 
as adverse drug effects, poor instructions, poor provider-
patient relationship, poor memory, and patient disagree-
ment with the need for treatment or inability to afford 
medication (Gusmão, Mion, Pierin, 2009; Ortega et al., 
2010). According to Giorgi (2006), to adhere to treatment, 
patients should know their own health conditions and the 
importance of blood pressure control, and should have ac-
cess to health services. These services should ensure that 
patients follow treatments throughout their lives.
CONCLUSIONS
Pharmacy benefit management (PBM) describes 
benefit programs that enable access to medicines through 
integrated information management. PBM is a useful tool 
to control and investigate medicine use profile, and may be 
used to identify and follow up medicine purchases for the 
treatment of patients diagnosed with chronic pathologies. 
However, PBM does not ensure that the user will take the 
therapeutic measures to keep blood pressure under control, 
or that medical prescriptions will be followed. In other 
words, PBM cannot evaluate medication consumption by 
patient or their adherence to antihypertensive treatment. 
Together with the use of the PBM tool, preventive medi-
cine programs should be developed to monitor treatment, 
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medical visits and changes in lifestyle (reduction of body 
weight, and physical activity), and should also include 
periodical phone calls or emails to enhance patient adher-
ence to antihypertensive treatment.
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